ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1786

Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study

Konstantinos Tselios1, Dafna D Gladman2, Jiandong Su3, Olga Ace4 and Murray Urowitz5, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Atherosclerosis, Cardiovascular disease, longitudinal studies and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies, the evolution over time and relative importance of these variables in the development of atherosclerotic cardiovascular events (CVEs) is not known. We aimed to determine the evolution of CVE risk factors over 15 years,

Methods:   250 female lupus patients (mean age at enrollment 44.5±12 years, mean disease duration 13.7±9.7 years) and 250 age-matched healthy women (mean age 44.1±14 years) were recruited between 1998 and 2000. All subjects had similarly low (3.2%) 10-year Framingham Risk Score (FRS) Variables assessed at study entry included family history of premature for coronary artery disease (CAD). CAD, hypertension, diabetes, dyslipidemia (total cholesterol, triglycerides, LDL, VLDL, HDL, lipoprotein a), smoking, physical activity, body mass index (BMI), menstrual status, use of oral contraceptives or hormone replacement therapy, serum creatinine, homocysteine and C-reactive protein. For lupus patients, SLEDAI-2K and the 3-year adjusted mean SLEDAI (AMS) (1998-2000 and 2005-2007) were calculated to quantify global disease activity. Additional parameters included antiphospholipid antibodies; information on antimalarials, prednisone and immunosuppressants were also collected. Subjects were followed for 15 years for the development of CVEs [angina, myocardial infarction (fatal, non-fatal), transient ischemic attack, stroke (fatal, non-fatal)]. Analysis was performed with SAS 9.3 software for 2000-2007 and 2008-2015; p<0.05 was considered significant.

Results:  SLE patients had consistently higher rates of CVEs, the difference becoming greater with longer follow up (p=0.0001). CVEs occurred in 41/210 patients (19.5%) and 8/138 controls (5.8%), mostly in the second part (2008-2015) (24/41, 58.5% vs. 17/41, 41.5% in patients, 4 CVEs in each part in controls). Coronary artery disease was more common in SLE (32/210, 15.2% vs. 5/138, 3.6%, p=0.0041). There was no significant difference for cerebrovascular disease (10/210, 4.8% vs. 3/138, 2.2%, p=0.213). SLE [HR=2.8, 95% CI 1.3-6.3], older age and triglycerides>2.8mmol/L were predictive of CAD in the early phase. In the late phase, hypertension, diabetes, dyslipidemia and high BMI were more prominent in patients who suffered a CVE. Time-adjusted disease activity (AMS) was lower in those late phase patients; however their cumulative prednisone dose between 2000-2007 was significantly higher. Of note, 60% of the new hypertension and all new diabetes cases were attributed to glucocoricoids. Thirty-one deaths occurred in patients (10 due to CVEs) and 6 in controls (none due to CVEs); all CVE-related deaths occurred between 2008 and 2015.

Conclusion:   SLE patients had a 4-fold increased risk for CVEs and all-cause mortality as compared to healthy controls after 15 years. Disease-related factors dominate cardiovascular risk during the early stages while traditional factors, partially related to corticosteroid treatment, play a significant role later in disease course.


Disclosure: K. Tselios, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5; J. Su, None; O. Ace, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman DD, Su J, Ace O, Urowitz M. Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/long-term-evolution-of-risk-factors-for-atherosclerotic-cardiovascular-events-in-systemic-lupus-erythematosus-in-a-large-case-control-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-evolution-of-risk-factors-for-atherosclerotic-cardiovascular-events-in-systemic-lupus-erythematosus-in-a-large-case-control-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology